Four Presentations to Discuss the State of the Neurotoxin Industry

IRVINE, Calif., April 23, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus”), a lifestyle aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today announced it will present during the inaugural Aesthetics Innovation Summit (AIS) on April 25 and at The Aesthetic Meeting, hosted by The American Society of Aesthetic Plastic Surgery (ASAPS), taking place April 26-May 1. Both meetings will be held in New York, NY.

In invitation-only panel presentations and on the scientific podium, Evolus executives will discuss the latest clinical research and the state of the neurotoxin industry, while highlighting the Company’s investigational neurotoxin DWP-450, (prabotulinumtoxinA), a 900 kilodalton (kDa) neuromodulator for the treatment of adult subjects with moderate to severe glabellar lines, also known as "frown lines.”

Murthy Simhambhatla, Ph.D., President and Chief Executive Officer of Evolus, commented, “The aesthetic neurotoxin industry has approached a major inflection point, with total sales of $945M in the U.S. in 2017¹ and an increasingly dynamic comeptitive landscape. At Evolus, we are creating an aesthetic platform for a new age to address a large and growing market. Directly ahead of ASAPS, the inaugural Aesthetic Innovation Summit will provide insight into the current state of the industry. We look forward to providing insight into our DWP-450 product candidate.”

“Our Phase III EVB-003 head-to-head comparative trial in the EU and Canada demonstrates that DWP-450 clearly met its primary endpoint at Day 30 in subjects with moderate to severe glabellar lines compared to onabotulinumtoxinA (Botox^®),” added Rui Avelar, M.D., Chief Medical Officer of Evolus. “We look forward to presenting these results during The Aesthetic Meeting and further discussing the merits of DWP-450 as a potential fresh alternative to other neurotoxins such as Botox during the Hot Topics Panel.”

Aesthetics Innovation Summit (AIS)

Panel: Clash of the Toxin Titans: Will the Products That Dominate Today Determine Tomorrow’s Market Leader?

• Overview: A two-part discussion between industry and clinical leaders to compare the various aesthetics offerings and debate the benefits or drawbacks of each
• Date: Wednesday, April 25^th at 11:20 am - 12:30 pm EDT
• Featuring: Murthy Simhambhatla, Ph.D., Chief Executive Officer of Evolus
• Session Moderator: W. Grant Stevens, MD, FACS

ASAPS’ The Aesthetic Meeting

Panel: What’s the Difference and Why Should I Start Using a New Toxin?

• Session: 2018 – The Year of New Toxins: Topical, Short-Acting, and Something Better Than Botox?
• Chairmen: Jamil Ahmad, MD, Tiffany McCormack, MD and Simeon Wall, Jr., MD
  • Featuring Rui Avelar, M.D., Chief Medical Officer of Evolus
• Date: Friday, April 27, 2018 at 1:15 – 1:30 pm EDT

Oral Presentation: A Phase III, Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled, Single Dose Trial to Demonstrate the Efficacy and Safety of PrabotulinumtoxinA in Adult Subjects for Treatment of Moderate to Severe Glabellar Lines

• Date: Sunday, April 29, 2018 at 8:45 – 8:50 am EDT
• Location: Hall E, Room 7 & 8
• Presenter: Dr. Per Heden

Oral Presentation: DWP-450, Purified Botulinum Toxin Type A, for the Treatment of Moderate-to-Severe Glabellar Lines in Adult Subjects: Results from a Multi-Center, Open Label, Repeat Dose, Long Term Exposure, Year Long Phase II Safety Study

• Date: Monday, April 30, 2018 at 12:00 – 12:05 pm EDT
• Location: Hall E, Room 7 & 8
• Presenter: Dr. Paul Lorenc

¹ Marc Goodman, Uy Ear, and Zidong Zhang, “UBS Specialty Pharmaceuticals Monthly Handbook,” UBS, Apr. 6, 2018, pp 56.

About PrabotulinumtoxinA
PrabotulinumtoxinA is a 900 kDa purified botulinum toxin type A complex. The product candidate's Biologics License Application (BLA) is currently under review by the U.S. Food and Drug Administration (FDA). The product candidate's Marketing Authorization Application (MAA) is currently also under review by the European Medicines Agency (EMA). The FDA application is for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. The EMA application is for temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity has an important psychological impact in adult patients.

About Evolus, Inc.
Evolus is a lifestyle aesthetics company dedicated to bringing advanced aesthetic procedures and treatments to physicians and consumers. Evolus focuses on the self-pay aesthetic market and its lead product candidate DWP-450 (prabotulinumtoxinA neuromodulator), an injectable 900 kDa purified botulinum toxin type A complex.

Evolus Contacts:

Media:
Kirsten Thomas, The Ruth Group
Tel: +1-508-280-6592
Email: kthomas@theruthgroup.com

Investor Contact:
Brian Johnston, The Ruth Group
Tel: +1 646-536-7028
Email: IR@Evolus.com